This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2019
  • /
  • 01
  • /
  • Trial of Rezum Water Vapor Therapy for benign pros...
Drug news

Trial of Rezum Water Vapor Therapy for benign prostatic hyperplasia is published in Urology.- Boston Scientific

Read time: 1 mins
Last updated:26th Jan 2019
Published:26th Jan 2019
Source: Pharmawand

Boston Scientific Corporation announced that data from a randomized clinical trial demonstrate that Rezum Water Vapor Therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH), provides durable results and preserves sexual function four years after treatment. The study, published online ahead of print by Urology, found that patients continued to experience significant and sustained improvement in their symptoms and quality of life over this period.

In particular, lower urinary tract symptoms were significantly improved within 3 months after thermal therapy and remained consistently durable (IPSS 46%, QOL 42%, Qmax 50%, BPH Impact Index 51%) throughout 4 years; outcomes were similarly sustained in crossover subjects at 3 years. Surgical retreatment rate was 4.4% over 4 years. No disturbances in sexual dysfunction were reported.

See: "Rezum Water Vapor Thermal Therapy For Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia: 4-Year Results From Randomized Controlled Study" Kevin T. McVary et al. Urology Published online: January 21, 2019 DOI:

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.